Niels Reichardt

Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK

Metabolic Renal Disease SL develops mass-spectrometry based tools for targeted metabolomics. It is a biotechnology company that specializes in the field of biometrics. The company's activity is centered in the development of analytical tools based in mass spectrometry and oriented to metabolomics for the identification, quantification and interpretation of metabolites in biofluids. The firm offers a range of applications, specially related to toxicology and pharmacological evaluation. Metabolic Renal Disease was founded in 2008 and is headquartered in San Sebastian, Spain.